Last reviewed · How we verify
Pioglitazone and Tretinoin
At a glance
| Generic name | Pioglitazone and Tretinoin |
|---|---|
| Sponsor | Phoenix Neurological Associates, LTD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML (PHASE2)
- Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone and Tretinoin CI brief — competitive landscape report
- Pioglitazone and Tretinoin updates RSS · CI watch RSS
- Phoenix Neurological Associates, LTD portfolio CI